Date |
Symbol |
Description |
Type |
Disease |
Designation |
Success Rating |
Q3 2016
|
TNXP |
|
Phase 3 Results |
Neurology |
Special Protocol Assessment |
|
03/29/2016
|
ACAD |
|
Advisory Panel |
Neurology |
Breakthrough Therapy, Priority Review |
|
05/01/2016
|
ACAD |
|
PDUFA |
Neurology |
Breakthrough Therapy, Priority Review |
|
01/03/2017
|
VCEL |
|
PDUFA |
Other |
None |
|
01/07/2017
|
ANAC |
|
PDUFA |
Other |
None |
|
Q3 2016
|
GNCA |
|
Phase 2b Results |
Infectious Disease |
None |
|
Q4 2016
|
GNCA |
|
Phase 2b Results |
Infectious Disease |
None |
|
09/15/2016
|
DVAX |
|
PDUFA |
Infectious Disease |
None |
|
Q2 2016
|
RIGL |
|
Phase 3 Results |
Autoimmune |
None |
|
Q3 2016
|
RIGL |
|
Phase 3 Results |
Autoimmune |
None |
|